Table 3. The influence of genetic factors on reported maternal adverse effects.

Gene	SNP			Global Minor AlleleFrequency (MAF):	Observed MAF in allstudy participants (N)	Allele		Percent of mothersreporting ADRS (N = 19)	Percent of healthy mothers (N = 218)		P Value
ABCB1	rs1128503			0.42	T = 0.445 (212)	TT		21	25		0.21
						TC		37	44		0.16
						CC		42	31		0.12
	rs2032582			0.34	A = 0.21 (100)	AA		21	16		0.19
					T = 0.21 (98)	AT		5	6		0.38
						GG		32	39		0.16
						GT		37	35		0.19
						GA		5	3		0.38
	rs1045642			0.40	T = 0.44 (207)	TT		26	21		0.19
						TC		32	45		0.10
						CC		42	34		0.15
COMT	rs4680			0.39	A = 0.43 (204)	AA		21	21		0.23
						AG		32	46		0.10
						GG		47	33		0.10
	rs4633			0.39	T = 0.42 (200)	CC		47	34		0.10
						CT		37	45		0.15
						TT		16	21		0.27
	rs4818			0.32	C = 0.65 (306)	CC		37	41		0.18
						CG		42	48		0.17
						GG		21	11		0.12
OPRM1			rs1799971	0.19	G = 0.22 (105)		AA	68		62		0.18
						AG		32	30		0.20
						GG		0	8		0.23
UGT 2B7		rs7439366		0.47	T = 0.44 (206)	CC CT TT		37 37 36	36 40 24		0.200.190.21

Minor allele frequency for polymorphisms in the p-glycoprotein transporter (ABCB1), cathechol-o-methyltransferase (COMT), mu-opioid receptor (OPRM1) and UDP glucuronosyltransferase (UGT) 2B7 in mothers reporting adverse drug reactions (ADR) in themselves compared to those that were asymptomatic (healthy). Significance value was set at P<0.05.